Table 2 Therapeutic regimens, survival outcomes in eligible studies

Exp vs con

Exp vs con

Exp/con

Exp/con

Exp/con

Exp/con

Lv et al

Lob 30 mg/m² d1,22 + 5FU 800 mg/m²d1–5,every 21 days for 2cycles vs DDP 100 mg/m² + 5FU 800 mg/m²d1–5,every 21 days for 2cycles

Lob 30 mg/m² 2 cycles vs DDP 100 mg/m² 2 cycles

IMRT

5 year: 88.2%/89%

75%/75.5%

86.6%/85%

87.7%/88.8%

Tang et al

Doc 65 mg/m2 d1 + Ned 80 mg/m2 d1, every 21 days for 2cycles vs Doc 65 mg/m2 d1 + DDP 80 mg/m2 d1, every 21 days for 2cycles

Ned 40 mg/m2 every week for 3cycles vs DDP 40 mg /m2 every week for 3cycles

IMRT

3 year: 87.5%/85.9%

3 year: 77.5%/74.9%

3 year: 86.7%/85.1%

3 year: 91.9%/91.7%

Linquan et al

NR

Ned 100 mg/m²d1 every 21 days for 3cycles vs DDP 100 mg/m² every 21 days for 3cycles

IMRT

5 year: 88.8%/89.4%

2 year: 88.0%/89.9% 5 year: 79.8%/81.4%

5 year: 90.4%/85.9%

5 year: 89.6%/92.6%

Liu et al

DDP 75 mg/m2 d1 + 5FU 800 mg/m²d1–5, every 21 days for 2–3 cycles vs Ned 75 mg/m² + 5FU 800 mg/m²d1–5, every 21 days for 2–3 cycles

Ned 75 mg/m²d1 every 21 days for 2cycles vs DDP 80 mg/m²d1 every 21 days for 2cycles

IMRT

3 year: 82.4%/79.4%

3 year: 72.6%/68.7%

3 year: 80.7%/77.0%

3 year: 86.2%/92.6%

Zhan et al

Doc 60–75 mg/m2 d1 + DDP 60–75 mg/m2 d1 + 5FU 500–600 mg/m2, d1–5, every 21 days for 1–4 cycles

Ned 80 mg/m2 d1, every 21 days orNed 30 mg/m2 d1 every week vs DDP 80 mg/m2 d1,every 21 days or DDP 30 mg/m2 d1 every week

IMRT

3 year: 90.7%/92.3%

3 year: 78.9%/79.4%

3 year: 82.4%/85.1%

3 year: 96.1%/93.3%

Imjai et al

NR

CBP 100 mg/m2 every week vs DDP 100 mg/m²d1 every 21 days for 3cycles

2D-CRT

3 year: 77.7%/79.2%

NR

3 year: 63.4%/60.9%

NR